Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mammary Carcinoma, Human”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01976169
What this trial is testing

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

Who this might be right for
Advanced Breast Cancer
University of Texas Southwestern Medical Center 29
Large-scale testing (Phase 3)Study completedNCT01126190
What this trial is testing

Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

Who this might be right for
Chemotherapy-induced Neutropenia
Teva Branded Pharmaceutical Products R&D, Inc. 381
Early research (Phase 1)Study completedNCT04147819
What this trial is testing

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Who this might be right for
Cancers With HER2 Expression
Bayer 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847
What this trial is testing

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Who this might be right for
Metastatic Triple Negative Breast Cancer
AstraZeneca 273
Not applicableStudy completedNCT02666261
What this trial is testing

A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany

Who this might be right for
Breast Cancer
Hoffmann-La Roche 15,000
Testing effectiveness (Phase 2)Study completedNCT01494662
What this trial is testing

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 140
Early research (Phase 1)Study completedNCT03523572
What this trial is testing

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Who this might be right for
Breast CancerUrothelial Carcinoma
Daiichi Sankyo 86
Not applicableUnknownNCT06338644
What this trial is testing

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.

Who this might be right for
Hormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastMetastatic Breast Cancer
Helwan University 100
Not applicableStudy completedNCT05155566
What this trial is testing

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

Who this might be right for
Breast Cancer Metastatic
Pfizer 847
Early research (Phase 1)Active Not RecruitingNCT06475937
What this trial is testing

DM001 in Patients With Advanced Solid Tumors

Who this might be right for
Breast NeoplasmsCarcinoma, Non-Small-Cell LungSolid Carcinoma
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. 128
Testing effectiveness (Phase 2)Active Not RecruitingNCT06334432
What this trial is testing

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHER2-negative Breast CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)+2 more
Nuvation Bio Inc. 466
Testing effectiveness (Phase 2)Study completedNCT00039793
What this trial is testing

Massage Therapy for Cancer-Related Fatigue

Who this might be right for
Breast NeoplasmsOvarian NeoplasmsProstatic Neoplasms+1 more
National Center for Complementary and Integrative Health (NCCIH) 45
Early research (Phase 1)Study completedNCT05759949
What this trial is testing

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+5 more
Relay Therapeutics, Inc. 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT04152499
What this trial is testing

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Who this might be right for
Epithelial Ovarian CancerGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+7 more
Klus Pharma Inc. 1,410
Early research (Phase 1)Active Not RecruitingNCT06746688
What this trial is testing

A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.

Who this might be right for
Breast CancerBreast Cancer Metastatic
ExpreS2ion Biotechnologies 40
Not applicableStudy completedNCT02658461
What this trial is testing

An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 36
Early research (Phase 1)Looking for participantsNCT04872166
What this trial is testing

BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Who this might be right for
Advanced Solid TumorMetastatic Breast Cancer
Edgewood Oncology Inc. 112
Early research (Phase 1)Active Not RecruitingNCT05277051
What this trial is testing

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Who this might be right for
Neoplasms
GlaxoSmithKline 152
Early research (Phase 1)Active Not RecruitingNCT04521686
What this trial is testing

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
CholangiocarcinomaChondrosarcomaGlioma+1 more
Eli Lilly and Company 200
Testing effectiveness (Phase 2)WithdrawnNCT02661100
What this trial is testing

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Who this might be right for
Non Small Cell Lung CancerAdvanced Triple Negative Breast CancerSmall Cell Lung Cancer+3 more
Case Comprehensive Cancer Center
Next Page